



WE AIM to change pregnancy care, to transform the experience into one with fewer uncertainties.



Safe Harbor Statement

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make.

The company has no obligation to provide any updates to these forward-looking statements, even if its expectations change, whether as a result of new information, future events or otherwise, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company’s Registration Statement on Form S-1, most recent Annual Report on Form 10-K, and/or subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company’s other filings with the SEC. The information in this presentation should be considered in conjunction with a review of the company’s filings with the SEC including the information in the company’s Registration Statement on Form S-1, most recent Annual Report on Form 10-K, and/or subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

In the U.S., maternal and neonatal mortality rates are increasing, signaling a need for improved healthcare and innovation.

One-third of pregnant women experience complications, often without warning, posing significant health risks for both mother and child.


Vision

Sera Prognostics aims to be a global leader in high-value women's health diagnostics, delivering pivotal information to physicians and mothers to improve the health of pregnant women and newborns, and to simultaneously improve the economics of pregnancy care.

Mission

Pregnancy complications occur frequently, often without warning. In the U.S., this is the reality for one-third of pregnancies. Sera Prognostics is transforming the pregnancy journey with innovative products aimed at identifying complications early and accurately. We provide personalized insights into the risk of preterm birth and other pregnancy complications, empowering all pregnant women and their caregivers with innovative products aimed at delivering better outcomes for mothers and babies.

The Pregnancy Company®



PREGNANCY OUTCOMES

Provides information to healthcare providers to guide personalized interventions

SPECIALTY LAB

Focuses on obstetric test offerings and analytics products

EMPOWERMENT

Aims to empower physicians and expectant mothers with actionable insights

RESEARCH- DRIVEN

Committed to driving advancements in maternal-fetal medicine through rigorous research and clinical trials

INNOVATIVE TESTS & PRODUCTS

Utilizes cutting-edge technologies such as proteomics and AI

GLOBAL IMPACT

Works towards shaping the future of pregnancy care worldwide

SOCIETAL IMPACT

Focusing on neonatal and maternal outcomes can yield numerous benefits for all members of society

Families: Decrease the burden linked to pregnancy complications

Payers: Improve outcomes and the economics of care delivery


Communities: Address growing health disparities in maternal care

Healthcare Providers: Provide tools to address unmet needs in pregnancy care

Self-insured Employers: Enhance employer healthcare for employees and their families

Policy: Support government programs targeting improvements in maternal healthcare

Improved pregnancy outcomes start with better information



Utilize proteomic testing
early in the pregnancy to
identify high-risk pregnancies

Target individuals identified
as high-risk for tailored
preventive treatments

Achieve healthier outcomes by
reducing morbidity, mortality, and
hospitalization time for newborns


Answers provided by **proteomics**.

Given the limitations of current screening practices for pregnancy complications, scientists at Sera discovered a biomarker prediction that fills a critical diagnostic gap.

Why Proteomics?

Personalized insights for each pregnancy. Proteomics provide insights into the biology of each pregnancy and go beyond genetic inheritance.

Early detection and intervention. Proteins reflect the functions of specific cells allowing for early detection and intervention before symptoms arise.



Sera's proprietary data assets and technology platform generate powerful insights

Biobank of Blood Samples

20,000 pregnant women

Clinical Outcomes Data

Multiple clinical utility studies

Demographic & Geographic Diversity

Broad sample collection across U.S. population

Global Dataset

North America, Europe, Asia and Africa

Advanced Mass Spectrometry

300+ proteins analyzed

Artificial Intelligence & Machine Learning


Discovering important predictors




POWERFUL INSIGHTS:

- **Early risk prediction** such as preterm birth or preeclampsia, before symptoms manifest.
- **Improving health outcomes** by identifying high-risk individuals and implementing targeted interventions
- **Shared decision-making** by empowering patients to make informed decisions regarding prenatal care
- **Reduced healthcare costs** through improvements in the health of the baby and reducing the need for the NICU
- **Research advancements** to help understanding the biology of pregnancy


Sera's technology platform transforms national averages into personalized insights



The national risk of a complicated pregnancy is 31%.



The probability of pregnancy complications range from 10 - 90%.




Utilizing proteomic markers and data analytics, Sera can identify a mother's pregnancy journey inclusive of her complication risk within a 4% margin.



NEAR TERM EXECUTION

Accelerate PreTRM
Adoption & Revenue



Addressing the Problem of Preterm Birth

1 in **10** babies are born too soon¹

Preterm birth contributes to **34.2%** of newborn deaths²

Causes numerous medical issues requiring more hospital time and pediatric visits^{3,4}



Reducing the health impacts of an early delivery with the PreTRM[®] Test

Challenges facing risk assessment for preterm birth

Up to half of all pregnant women who deliver prematurely have no known risk factors^{1,2}

Knowing the Risk Enables Informed Action

PreTRM's sensitivity of 88% allows healthcare providers to detect higher-risk patients who would have been missed with current screening tools³

Reduce the impacts of preterm birth

Recent studies demonstrated an 18% reduction in severe neonatal morbidity and mortality when higher-risk pregnancies identified by the PreTRM Test received risk-reduction interventions compared to standard care⁴

A strong foundation of evidence

CLINICAL STUDIES

ANALYTICAL VALIDATION

CLINICAL VALIDATION

CLINICAL UTILITY

ECONOMIC UTILITY

CLINICAL MASS SPECTROMETRY / Bradford et al., 2017

- Achieved robust analytical validation of protein biomarkers for risk of spontaneous preterm birth



PAPR / Saade et al., 2016

- AJOG editor's choice establishing PreTRM[®] analytical validation



ACCORDANT THRESHOLD / Burchard et al., 2021

- Validated PreTRM threshold for clinical decision-making for risk of spontaneous preterm birth (sPTB) and adverse maternal and neonatal outcomes in cohorts with diverse racial and ethnic backgrounds



AJP REPORTS / Caughey et al., 2016

- Empirical data demonstrating the clinical and cost impact of prognostic test for early detection of preterm birth



Building on the foundation with new clinical utility evidence

CLINICAL STUDIES

ANALYTICAL
VALIDATION

CLINICAL
VALIDATION

CLINICAL
UTILITY

ECONOMIC
UTILITY

COST-EFFECTIVENESS OF A PROTEOMIC TEST FOR PRETERM BIRTH PREDICTION / Grabner et al., 2021

Showed both improved neonatal outcomes and reduced immediate and long-term treatment costs associated with premature birth, when compared to routine care



PREVENT / Branch et al., 2021

Study demonstrates positive impact of the company's PreTRM® test-and-treat strategy on improving neonatal healthcare



ACCORDANT CU (TREETOP) / Burchard et al., 2022

Combines real-world observational data with simulation to project significant potential improvements in neonatal outcomes among racially and ethnically diverse populations



PREDICTION AND PREVENTION OF PTB / Combs et al., 2023

Study concludes that screening with the PreTRM® Test followed by care management intervention and LDA prolonged pregnancy and reduced adverse outcomes



AVERT / Hoffman et al., 2023

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay



PRIME / Iriye et al., ongoing

Further investigates the value of implementing the PreTRM® test-and-treat strategy to reduce both adverse singleton pregnancy outcomes and overall healthcare costs




The AVERT PRETERM Trial studied the health impacts of the PreTRM[®] test-and-treat Strategy

Neonatal outcomes after proteomic biomarker guided intervention: the AVERT PRETERM TRIAL



- The study took place from June 2018 - September 2020 at ChristianaCare Hospital (Newark, DE)
- The proportion of Black women in both arms was 26.5%, reflecting the racial diversity in the study site's patient population

Study Design

Historically Controlled



Reduce the time the baby spends in the hospital on average by one week



Severe morbidity and mortality rates were significantly reduced

NMI scores were significantly reduced in the prospective arm vs the historical arm

(OR 0.81; 95% CI 0.67-0.98; P=0.03)

18% reduction in severe neonatal morbidity and mortality*


(probability of NMI ≥ 3)




***Severe neonatal morbidity and mortality are defined as Neonatal Composite Morbidity & Mortality Index (NMI) ≥ 3**

- 1-4 score given (4 = infant mortality)
- The score increases by 1 point for each additional diagnosis of:
 - Respiratory distress syndrome
 - Bronchopulmonary dysplasia
 - Intraventricular hemorrhage grade III or IV
 - All stages of necrotizing enterocolitis
 - Periventricular leukomalacia
 - Proven severe sepsis
- The scale uses NICU stays to determine index scores if the length of stay gives a higher score than concomitant diagnoses: 1-4 days give a score of 1, 5-20 days a score of 2 and >20 days a score of 3.1

Increase gestational age at birth to improve outcomes for those at risk of earliest delivery



Reduce the time the neonate spends in the hospital on average by one month for those at risk of earliest delivery



Historical (Standard of Care)	155	155	147	131	121	114	98	89	79	71	63	56	53	52	50	47	45	45
Prospective (Test and Treat)	15	15	15	11	8	8	7	6	5	4	3	2	2	2	2	2	2	2

28 Day

Reduction in neonatal length of hospital stay for patients born before 32 weeks' gestation

Advancing PreTRM[®]'s Evidence Development for Enhanced Pregnancy Outcomes

Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME)

A pioneering clinical trial assessing the efficacy of the PreTRM Test and preventive interventions in lowering the occurrence of adverse pregnancy outcomes.



Achievement of a primary endpoint resulted in the early termination of the study.

Published Elevance Cost-Effectiveness Model

Elevance Claims Data

Analysis of >40,000 mothers and babies within commercially insured Elevance membership

- Evaluated screening with PreTRM along with proactive interventions given to PreTRM-higher risk patients vs. standard care
- Demonstrated robust clinical and economic impacts of the PreTRM test-and-treat strategy

Results

- 20% reduction in preterm birth rates
- \$1,608 gross savings, excluding a \$745 PreTRM list price per pregnant woman (amortized over all pregnancies including non-tested)
- 10% reduction in neonatal intensive care admissions
- 7% reduction in overall hospital length-of-stay
- 33% reduction in births <32 weeks
- The test-and-treat strategy is dominant with respect to cost savings across all conservative probabilistic sensitivity analyses and scenarios



Pregnancy Product Road Map



More than just the PreTRM® Test

2023

2024

2025

2026

2027

PRETRM TEST

PREDICTIVE ANALYTICS PRODUCT

TIME-TO-BIRTH TEST

PREGNANCY RISK
PREDICTION PANEL



Commercially Available



Estimated Product Launch

Developing a portfolio to provide better answers to life changing questions

Am I at risk for a premature birth?

PreTRM® Test

To provide a woman and her physician a risk assessment for spontaneous preterm birth

What do pregnancies like mine look like?

Predictive Analytics Product

To show a woman the most common outcomes in pregnancies of other women with similar clinical and demographic characteristics

When will my baby be born?

Time-to-Birth Test







To provide a more accurate estimate of when a mother's baby will be delivered for the purposes of planning maternity leave, travel, visitors, etc. This is a lifestyle and wellness test rather than a clinical test.

Am I at risk for the common pregnancy complications?

Pregnancy Risk Prediction Panel Test

To provide a woman and her physician a risk assessment for multiple pregnancy complications assessing both High Risk (rule-in) and Low Risk (rule-out) results in a single test

Robust Biomarker Pregnancy Pipeline

PREDICTOR	Est. U.S. Prevalence in Pregnancy	DISCOVERY	VERIFICATION	VALIDATION	COMMERCIALIZED	Upcoming Expected Milestones and Anticipated Timing
PreTRM® Test for Risk of Preterm Birth	10%					<ul style="list-style-type: none"> • Publications of additional clinical and economic outcome studies in 2024-2025 • PRIME: interim analysis complete; final in late 2024
Time-to-Birth	N/A					<ul style="list-style-type: none"> • Publication of data in 2024-2025
Predictive Analytics Product	N/A					<ul style="list-style-type: none"> • Early market testing in progress
Pregnancy Risk Prediction Panel	31%					<ul style="list-style-type: none"> • Validation underway to assess which risk factors and other major pregnancy complications to be included; began market research
Preeclampsia	5-8%					<ul style="list-style-type: none"> • Public release of validation data in 2024 • Product profile development underway
Fetal Growth Restriction (FGR)	3-7%					<ul style="list-style-type: none"> • Biomarker discovery completed • Product profile development underway



Technology Road Map

Transitioning analyses for cost-effectiveness, faster turnaround times, and enhanced market accessibility

- Diagnostic tests rely on biological samples, but there are current limitations on collection and transport
- Sera is shifting to ambient conditions for sample transport to enhance the patient and provider experience and improve access to testing

SERA'S APPROACH TO SIMPLIFYING BLOOD COLLECTION

**Venipuncture and
frozen or ambient
serum shipment**

Transitioning from frozen
shipments to ambient
conditions for sample transport

Completed

**Venipuncture
and ambient blood
shipment**

Adding whole-blood
sample types to test menus,
alongside serum

Ongoing

**Capillary blood
draw and ambient
shipment**

Developing capillary blood
draw capabilities without the need
for venipuncture

Ongoing

Transitioning analyses for cost-effectiveness, faster turnaround times, and enhanced market accessibility

- Sera utilizes proteomic methods for discovering, verifying, and validating pregnancy tests.
- The PreTRM[®] test, a prime example, is commercially launched using mass spectrometry, enabling swift market access and evidence accumulation.
- Immunoassays may offer cost-effectiveness, rapid turnaround times, and enhanced market accessibility via point-of-care testing or kit distribution.
- Antibodies are developed for PreTRM analytes to facilitate immunoassay creation.
- Immunoassay methods at Sera include affinity-capture mass spectrometry (AC-MS) and enzyme-linked immunosorbent assays (e.g., ELISA, ECLIA), with the latter typically requiring two antibodies per analyte.
- AC-MS serves as a transitional tool to ELISA/ECLIA platforms.
- In some instances, Sera directly transitions from proteomics discovery to commercialization via an ELISA format.



Sera Leadership Team



Zhenya Lindgardt

President & CEO

- Former CEO, The Commons Project Foundation
- Former VP of Platform and Customer Engagement, Uber Technologies
- Former Senior Partner and Managing Director, The Boston Consulting Group
- MBA, Harvard University



Austin Aerts

Chief Financial Officer

- Former VP, Finance and Corporate Controller, Sera
- Former finance team member, Myriad
- Former auditor, Ernst & Young LLP
- Master of Accounting University of Utah; CPA



Jay Boniface, Ph.D.

Chief Scientific Officer




Michael Foley, M.D.

Medical Advisor



Paul Kearney, Ph.D.

Chief Data Officer



Doug Roach

VP of Commercial



Benjamin Jackson

General Counsel



Robert G. Harrison

Chief Information Officer



Thank You